コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 fects that likely contribute to HPV-mediated cancer progression.
2 ffsetting the effects of obesity on prostate cancer progression.
3 tracellular matrix (ECM) is a key feature of cancer progression.
4 ssary for beta-adrenergic signaling-promoted cancer progression.
5 (VHL) gene occurs in 90% of CC-RCC, driving cancer progression.
6 ng embryonic development, wound healing, and cancer progression.
7 ponse, which has a critical role in prostate cancer progression.
8 well demonstrated to play important roles in cancer progression.
9 of MTA1-SGK1 axis by a physiologic signal in cancer progression.
10 gnificance of FAD-dependent LSD1 activity in cancer progression.
11 al processes, including neurodevelopment and cancer progression.
12 overexpression of ADAMs could correlate with cancer progression.
13 ortant role in many biological processes and cancer progression.
14 ular adaptive responses that enable to drive cancer progression.
15 portant for cell motility, and implicated in cancer progression.
16 rious signaling events leading to metastatic cancer progression.
17 kinases (LIMK1 and LIMK2) to abrogate breast cancer progression.
18 significance of these receptors in prostate cancer progression.
19 regarded as a crucial contributing factor to cancer progression.
20 renergic signaling is involved in pancreatic cancer progression.
21 smembrane co-receptor neuropilin-1 (NRP1) in cancer progression.
22 ling in T cells is important for controlling cancer progression.
23 tion in beta-adrenergic signaling to promote cancer progression.
24 differential response to LPA treatment with cancer progression.
25 ularity provide a potential avenue to thwart cancer progression.
26 cell EMT may be useful as a therapy to block cancer progression.
27 ns and have been shown to be modified during cancer progression.
28 field defects which are selected for during cancer progression.
29 GRP78, TF expression/activity, and prostate cancer progression.
30 s and noncoding regions of the genome during cancer progression.
31 cancer and plays a critical role in prostate cancer progression.
32 1 (FoxA1) are significant factors in breast cancer progression.
33 acrophage (TAM) significantly contributes to cancer progression.
34 n the relationship between schizophrenia and cancer progression.
35 en our understanding of driver mechanisms in cancer progression.
36 nimal models suggest that they contribute to cancer progression.
37 eristic of many cancers that is critical for cancer progression.
38 nt FDA approval of several drugs that reduce cancer progression.
39 le in tumor escape from immune system during cancer progression.
40 nterleukin (IL)-1 signalling promotes breast cancer progression.
41 rs critical genes implicated in hallmarks of cancer progression.
42 ssor mechanisms it overcomes to drive breast cancer progression.
43 nd this persistence has been associated with cancer progression.
44 g environmental pressures encountered during cancer progression.
45 and disruption of either is commonly seen in cancer progression.
46 nmeasurable protein isoforms responsible for cancer progression.
47 s epigenetic regulation of metastatic breast cancer progression.
48 a critical microenvironmental factor driving cancer progression.
49 ociated either to tissue morphogenesis or to cancer progression.
50 mutation status does not accurately predict cancer progression.
51 coherent modules that might be relevant for cancer progression.
52 ave been previously implicated in colorectal cancer progression.
53 ancer metastasis is the most deadly stage in cancer progression.
54 hain component cytochrome c oxidase (CcO) in cancer progression.
55 ium and/or PTHrP levels contribute to breast cancer progression.
56 microenvironment and play a complex role in cancer progression.
57 y mechanisms of the beta-catenin activity in cancer progression.
58 ting the adhesion and migration machinery in cancer progression.
59 -lipoxygenase (5-LO) have been implicated in cancer progression.
60 d tumors, which controls multiple aspects of cancer progression.
61 nt a potential therapy for inhibiting breast cancer progression.
62 her support a role for the nervous system in cancer progression.
63 ling pathway has been implicated in prostate cancer progression.
64 en receptor agonist, which promotes prostate cancer progression.
65 ant TP53 gene does not systematically induce cancer progression.
66 f embryonic development, tissue fibrosis and cancer progression.
67 nergistically to promote invasiveness during cancer progression.
68 enesis, and it appears to be a gatekeeper to cancer progression.
69 ng, tissue regeneration, organ fibrosis, and cancer progression.
70 including regeneration, differentiation, and cancer progression.
71 d from WAT, recruited by tumours and promote cancer progression.
72 downstream of plexin-B1 function in prostate cancer progression.
73 rging hallmarks required for oncogenesis and cancer progression.
74 isms of action of eritoran in reducing colon cancer progression.
75 d to be a pivotal cytokine promoting ovarian cancer progression.
76 g its promoting role in BMP6-driven prostate cancer progression.
77 tations and representing different stages of cancer progression.
78 P1 protein levels are decreased during renal cancer progression.
79 nes and activates proliferation genes during cancer progression.
80 he role of MTA1-DNMT3a-IGFBP3 axis in breast cancer progression.
81 ularization, and local and metastatic breast cancer progression.
82 he cellular dNTP pool and has been linked to cancer progression.
83 that promotes the Warburg effect and breast cancer progression.
84 n factor is a critical barrier to pancreatic cancer progression.
85 lular functions that play important roles in cancer progression.
86 nic cascade, might inhibit tumorigenesis and cancer progression.
87 studies indicate that its expression favors cancer progression.
88 ith immunopathology, autoimmune disease, and cancer progression.
89 signaling promote angiogenesis and prostate cancer progression.
90 rocal crosstalk between signaling and CME in cancer progression.
91 n and localization may have implications for cancer progression.
92 ylation (OXPHOS) plays a crucial role during cancer progression.
93 ting that FBXL4 loss contributes to prostate cancer progression.
94 e examined the effects of Keap1 loss in lung cancer progression.
95 amic and conditional miRNA regulation during cancer progression.
96 e transcription, promoting tumorigenesis and cancer progression.
97 duced by Adrb2 deletion and rescued prostate cancer progression.
98 sengers accumulate and can collectively slow cancer progression.
99 rtant therapeutic tool to antagonize EMT and cancer progression.
100 to infer the evolutionary history of breast cancer progression.
101 fective therapeutic strategy against ovarian cancer progression.
102 .Tumor associated macrophages (TAMs) promote cancer progression.
103 n inhibitors as a strategy to block prostate cancer progression.
104 n microbial evolution of drug resistance and cancer progression.
105 remains the holy-grail in the battle against cancers progression.
106 nteraction effects in evolutionary models of cancer progression, a crucial step towards making clinic
107 ellular secreted factor in the prevention of cancer progression across multiple solid tumor types.
108 serves as a critical immunomodulator in lung cancer progression, acting to drive immune escape via a
109 sympathetic nervous system (SNS) and drives cancer progression, although the pathways of tumour cell
110 cells in the tumor microenvironment modulate cancer progression and are attractive therapeutic target
113 ivator that has been associated with bladder cancer progression and cisplatin resistance in ovarian c
115 optotic Bcl-2 family proteins contributes to cancer progression and confers resistance to chemotherap
116 lly focus on mechanotransduction pathways in cancer progression and describe in detail the key signal
117 tive Wnt/beta-catenin signaling is linked to cancer progression and developmental abnormalities, maki
119 o support specific translation during breast cancer progression and highlight a functional link betwe
120 thioredoxin-1 (TRX1) increases with prostate cancer progression and in androgen-deprived CRPC cells,
121 gm to study ERalpha regulation during breast cancer progression and indicates a role of FOXC1 in the
124 dvantage" relation among driver mutations in cancer progression and investigate its applicability to
125 FGF signaling including angiogenesis during cancer progression and is upregulated in various cancers
126 l mechanism by which obesity promotes breast cancer progression and lays out a foundation to block NL
128 olved in chronic pancreatitis and pancreatic cancer progression and metastasis remain poorly defined.
129 te cancer suppressor gene, which may prevent cancer progression and metastasis through controlling ce
146 can American women and contributes to breast cancer progression and numerous chronic conditions.
147 tical new role in the regulation of prostate cancer progression and offer a novel alternative target
151 clarifying the macroenvironmental effect of cancer progression and provide new potential approaches
154 ible therapeutic target involved in prostate cancer progression and relapse post androgen ablation th
156 Loss of 4E-BP1 expression has been linked to cancer progression and resistance to mTOR inhibitors, bu
158 signaling is a targetable driver of prostate cancer progression and serves as a biomarker of poor cli
159 how individual family members participate in cancer progression and small molecule inhibitors such as
160 votal regulator of AR signaling and prostate cancer progression and suggest a functional intersection
162 metastases emerge late during primary breast cancer progression and that additional driver mutations
163 cated G protein-coupled-receptors (GPCRs) in cancer progression and the acquisition of TIC phenotypes
164 n cancer has been linked to drug resistance, cancer progression and the presence of cancer cells with
165 n widely considered as an approach to combat cancer progression and therapeutic resistance, but a lim
171 defining the pathways that are limiting for cancer progression and understanding the context specifi
173 target genes are involved in key aspects of cancer progression, and are associated with clinical out
178 eal the mutation accumulation history, track cancer progression, and identify the mutations related t
179 tumor microenvironment to support or hinder cancer progression, and in this context outline gaps in
180 LRX1) has been implicated in viral response, cancer progression, and inflammatory disorders; however,
183 ces on their host ECM during development and cancer progression, and suggest indirect mechanical chan
187 l tumor-suppressing mechanism that restrains cancer progression at premalignant stages, in part by ca
188 genesis is key for a better understanding of cancer progression, biomarker identification and the des
189 ams important in both normal ontogenesis and cancer progression broadly fall into three domains: the
190 ating tumor cells (CTCs) have been linked to cancer progression but are difficult to isolate, as they
191 and their pathways are involved in prostate cancer progression, but few kinases have been mechanisti
192 outy (Spry) proteins have been implicated in cancer progression, but their role in triple-negative br
193 report that a 0.1 Gy radiation dose reduces cancer progression by deactivating the JAK1/STAT3 pathwa
194 ) contributes to cellular transformation and cancer progression by disrupting key metabolic signaling
195 ators specifically inhibit debris-stimulated cancer progression by enhancing clearance of debris via
196 lates PML via ubiquitination to promote lung cancer progression by fostering an immunosuppressive and
198 ke cells (CSC) have been proposed to promote cancer progression by initiating tumor growth at distant
199 and/or mechanical forces, can promote breast cancer progression by modulating NF-kappaB activation.
200 B (CtsB) contributes to atherosclerosis and cancer progression by processing the extracellular matri
201 ndent oxidoreductase drives angiogenesis and cancer progression by promoting TGM2-dependent invasion.
202 p120 catenin and S1P/S1pr2 signaling enhance cancer progression by regulating epithelial cell invasio
203 s associated with inflammatory disorders and cancer progression by releasing regulatory membrane-teth
204 nction integral protein, in inhibiting colon cancer progression by serving as the common rheostat of
206 alterations of HER2-positive BC cells during cancer progression can occur in a physical and signallin
207 Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-
208 rs whose deregulation has been associated to cancer progression, chemoresistance, invasiveness, and m
209 vely characterized a cellular model of colon cancer progression consisting of four defined derivative
210 ency of radiation-induced transformation and cancer progression differed in 3D compared to 2D culture
211 ive initiation factor eIF2A is essential for cancer progression, during which it mediates initiation
213 iated by RT-activated CAF worsens colorectal cancer progression, establishing a preclinical rationale
214 ine IGF1/IGF1R signaling promotes colorectal cancer progression, establishing a preclinical rationale
215 ney cancers, possibly reflecting accelerated cancer progression, etiologic heterogeneity, or risk fac
217 editing has recently emerged as a driver of cancer progression, genomic amplification combined with
222 eptor 4 (TLR4) has been implicated in breast cancer progression, however, its clinically relevant end
223 cover genetic mutations that enable prostate cancer progression; identify mouse models for studying p
224 epidemiology of smoking-associated prostate cancer progression, illuminating a novel candidate drive
225 tal features of the TME in promoting thyroid cancer progression, illuminating candidate therapeutic t
226 the relationship between the TME and thyroid cancer progression in a mouse model where thyroid-specif
227 in prostate cancer, has been shown to block cancer progression in an androgen-independent manner.
228 ptor as promising stromal targets to confine cancer progression in combination with conventional or t
233 rrelated with RSK2 expression and metastatic cancer progression in primary patient tumor samples.
237 d in pancreatic carcinoma and contributes to cancer progression, in part, through the specific DNA de
238 during human aging, in tissues during colon cancer progression, in telomere-related diseases such as
239 d Met are implicated in several hallmarks of cancer progression including sustained angiogenesis, enh
240 cancer patients and has an important role in cancer progression, including promoting drug resistance
244 the function of Nectin-4 shedding in ovarian cancer progression is critical to facilitate its develop
247 at the evolutionary trajectory of pancreatic cancer progression is gradual because each alteration is
255 and alphavbeta3, which are both relevant in cancer progression, is investigated by simultaneous elec
256 ogical processes including wound healing and cancer progression, is sensitive to environmental stiffn
258 strategy that enables the construction of a cancer progression model using static tumor sample data.
259 netic modulator of cell invasion during lung cancer progression.NatD is an acetyltransferase responsi
261 c or minimally symptomatic men with prostate cancer progression on androgen-deprivation therapy (ADT)
262 amide significantly reduced risk of prostate cancer progression or death compared with bicalutamide i
264 biomarkers and novel therapeutic targets for cancer progression, particularly for predicting and prev
266 ys/transcription factors involved in ovarian cancer progression, poor clinical outcome, and chemother
268 encounter are different during the stages of cancer progression-primary tumor, metastasis, and at the
269 portant determinant for inflammation-induced cancer progression, rather than inflammatory response.
271 mechanistic link between obesity and breast cancer progression remains unclear, and there has been n
274 prognostic markers than two other markers of cancer progression, S100A4 and MACC1, and clustering of
275 Analysis of 17 cancer developmental and 27 cancer progression signatures revealed a consistent tumo
276 In this study, we determined that colorectal cancer progression specimens invariably harbored lesions
277 lanoma cell lines corresponding to different cancer progression stages using the SECM substrate gener
278 h oncogenic and tumour-suppressing roles for cancer progression, such as the insulin-like growth fact
279 endent, miRNA-independent role of Alu RNA in cancer progression that could bring mobile element trans
280 enes is a major rate-limiting step in breast cancer progression that prevents the formation of new co
281 s or mutation of PPP2R1A might contribute to cancer progression, the effects of overexpression or mut
282 While endothelial cells are key players in cancer progression, the influence of tumor stiffness on
283 blasts and cancer cells generate signals for cancer progression, therapy resistance, and inflammatory
284 been implicated in hypoxia/HIF-1-associated cancer progression through largely unknown mechanisms.
285 pliced isoforms of the Fas gene, involved in cancer progression through regulation of programmed cell
286 products in the microenvironment during lung cancer progression through regulation of T cells and sug
287 play a significant role in enabling prostate cancer progression to NEPC, whereas IL-8 and MAPK/ERK pa
288 L loss may contribute to mTOR activation and cancer progression via dysregulation of basal DDIT4 gene
289 hat Slug-upregulated miR-221 promotes breast cancer progression via reducing E-cadherin expression.
291 possible CcO dysfunction as a biomarker for cancer progression was supported by data showing that es
292 he function of TGF-beta signaling in bladder cancer progression, we conditionally knocked out the Tgf
293 ircRNAs might be regulated during colorectal cancer progression, we used three isogenic colon cancer
294 t can break immunological tolerance and halt cancer progression, whereas on the contrary allergen imm
295 expression of initiator methionine tRNA and cancer progression, whereby elevated levels of this tRNA
296 ation and EMT, hence suppressed the invasive cancer progression, which is similar with the result of
297 energic signaling have been shown to promote cancer progression, whose underlying mechanisms are larg
298 ements in these developmental pathways drive cancer progression with a particular focus on how they h
299 aling axis that is activated during prostate cancer progression, with implications for therapeutic ta
300 ment mediate bone metastasis during prostate cancer progression, with potential implications for prog
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。